CONTEXT: Previous studies have suggested vitamin D insufficiency is associated with increased obesity; however, the relationship between 25-hydroxyvitamin D (25[OH]D) and 1,25-dihydroxyvitamin D (1,25[OH](2)D) and measures of adiposity has not been well characterized in minority populations. OBJECTIVE: The objective of the study was to examine the relationship between levels of 25[OH]D and 1,25[OH](2)D and measures of adiposity in Hispanic and African-Americans at baseline and on change in these measures over time. DESIGN AND SETTING: The Insulin Resistance Atherosclerosis (IRAS) Family Study examined 917 Hispanics and 439 African-Americans at baseline and again 5.3 yr later (n = 1081 at follow-up). MAIN OUTCOME MEASURE: 25[OH]D (nanograms per milliliter) and 1,25[OH](2)D (picograms per milliliter) were measured at baseline. Abdominal sc adipose tissue (SAT), visceral adipose tissue (VAT; both determined by computed tomography scan), and body mass index (BMI) were measured at baseline and follow-up. RESULTS: 25[OH]D was inversely associated with BMI, VAT, and SAT in both populations at baseline (P < 0.001). 25[OH]D was marginally inversely associated with baseline visceral fat to sc fat ratio in African-Americans (P = 0.049) but not Hispanics. 1,25[OH](2)D was inversely associated with BMI (P < 0.0001, P = 0.002) and VAT (P = 0.0005, P = 0.012) in Hispanics and African-Americans, respectively, whereas 1,25[OH](2)D was inversely associated with SAT in Hispanics (P < 0.0001) and with visceral fat to sc fat ratio in African-Americans (P = 0.02). Adjusting for 25[OH]D attenuated these associations; 1,25[OH](2)D remained associated with BMI in both populations (P < 0.05) and with SAT (P = 0.004) in Hispanics. No significant associations between 5-yr change in adiposity and 25[OH]D or 1,25[OH](2)D were seen. CONCLUSIONS: Vitamin D levels were inversely associated with baseline BMI, SAT, and VAT in Hispanic and African-Americans but were not associated with 5-yr change in adiposity.
CONTEXT: Previous studies have suggested vitamin Dinsufficiency is associated with increased obesity; however, the relationship between 25-hydroxyvitamin D (25[OH]D) and 1,25-dihydroxyvitamin D (1,25[OH](2)D) and measures of adiposity has not been well characterized in minority populations. OBJECTIVE: The objective of the study was to examine the relationship between levels of 25[OH]D and 1,25[OH](2)D and measures of adiposity in Hispanic and African-Americans at baseline and on change in these measures over time. DESIGN AND SETTING: The Insulin Resistance Atherosclerosis (IRAS) Family Study examined 917 Hispanics and 439 African-Americans at baseline and again 5.3 yr later (n = 1081 at follow-up). MAIN OUTCOME MEASURE: 25[OH]D (nanograms per milliliter) and 1,25[OH](2)D (picograms per milliliter) were measured at baseline. Abdominal sc adipose tissue (SAT), visceral adipose tissue (VAT; both determined by computed tomography scan), and body mass index (BMI) were measured at baseline and follow-up. RESULTS: 25[OH]D was inversely associated with BMI, VAT, and SAT in both populations at baseline (P < 0.001). 25[OH]D was marginally inversely associated with baseline visceral fat to sc fat ratio in African-Americans (P = 0.049) but not Hispanics. 1,25[OH](2)D was inversely associated with BMI (P < 0.0001, P = 0.002) and VAT (P = 0.0005, P = 0.012) in Hispanics and African-Americans, respectively, whereas 1,25[OH](2)D was inversely associated with SAT in Hispanics (P < 0.0001) and with visceral fat to sc fat ratio in African-Americans (P = 0.02). Adjusting for 25[OH]D attenuated these associations; 1,25[OH](2)D remained associated with BMI in both populations (P < 0.05) and with SAT (P = 0.004) in Hispanics. No significant associations between 5-yr change in adiposity and 25[OH]D or 1,25[OH](2)D were seen. CONCLUSIONS:Vitamin D levels were inversely associated with baseline BMI, SAT, and VAT in Hispanic and African-Americans but were not associated with 5-yr change in adiposity.
Authors: Capri G Foy; Fang-Chi Hsu; Steven M Haffner; Jill M Norris; Jerome I Rotter; Leora F Henkin; Michael Bryer-Ash; Yii-Der I Chen; Lynne E Wagenknecht Journal: Am J Hypertens Date: 2008-06-19 Impact factor: 2.689
Authors: N Vilarrasa; J Maravall; A Estepa; R Sánchez; C Masdevall; M A Navarro; P Alía; J Soler; J M Gómez Journal: J Endocrinol Invest Date: 2007-09 Impact factor: 4.256
Authors: Corinne D Engelman; Tasha E Fingerlin; Carl D Langefeld; Pamela J Hicks; Stephen S Rich; Lynne E Wagenknecht; Donald W Bowden; Jill M Norris Journal: J Clin Endocrinol Metab Date: 2008-07-01 Impact factor: 5.958
Authors: Kristen G Hairston; Ann Scherzinger; Capri Foy; Anthony J Hanley; Orita McCorkle; Steven Haffner; Jill M Norris; Michael Bryer-Ash; Lynne E Wagenknecht Journal: Diabetes Care Date: 2009-06-01 Impact factor: 17.152
Authors: Yamilka Abreu-Delgado; Raymond A Isidro; Esther A Torres; Alexandra González; Myrella L Cruz; Angel A Isidro; Carmen I González-Keelan; Priscilla Medero; Caroline B Appleyard Journal: World J Gastroenterol Date: 2016-04-07 Impact factor: 5.742
Authors: Paulette D Chandler; Lu Wang; Xi Zhang; Howard D Sesso; Manickavasagar V Moorthy; Obiageli Obi; Joshua Lewis; Richard L Prince; Jacqueline S Danik; JoAnn E Manson; Meryl S LeBoff; Yiqing Song Journal: Nutr Rev Date: 2015-07-14 Impact factor: 7.110
Authors: Anne Gangloff; Jean Bergeron; Isabelle Lemieux; Angelo Tremblay; Paul Poirier; Natalie Alméras; Jean-Pierre Després Journal: Int J Obes (Lond) Date: 2019-03-29 Impact factor: 5.095
Authors: Susan Cheng; Joseph M Massaro; Caroline S Fox; Martin G Larson; Michelle J Keyes; Elizabeth L McCabe; Sander J Robins; Christopher J O'Donnell; Udo Hoffmann; Paul F Jacques; Sarah L Booth; Ramachandran S Vasan; Myles Wolf; Thomas J Wang Journal: Diabetes Date: 2009-10-15 Impact factor: 9.461